No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
VNDA240621C5000
- 0.30
- +0.05+20.00%
15min DelayClose May 31 16:00 ET
0.30High0.30Low
0.30Open0.25Pre Close207 Volume3.17K Open Interest5.00Strike Price6.21KTurnover56.12%IV4.21%PremiumJun 21, 2024Expiry Date0.11Intrinsic Value100Multiplier19DDays to Expiry0.19Time Value100Contract SizeAmericanOptions Type0.6007Delta0.5885Gamma15.72Leverage Ratio-0.0071Theta0.0014Rho9.44Eff Leverage0.0045Vega
Intraday
- 5D
- 1D
News
Vanda Pharmaceuticals to Commercialize Treatment of Multiple Sclerosis in the US
Vanda Pharmaceuticals (VNDA) said late Thursday it is now allowed to commercialize Ponvory, or ponesimod, in the US. The company said the move follows the transfer of ownership of the US new drug appl
Vanda Pharmaceuticals Announces Participation in the Jefferies 2024 Global Healthcare Conference
WASHINGTON, May 30, 2024 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that the company will participate in the Jefferies 2024 Global Healthcare Conference in New
Express News | Vanda Pharmaceuticals Gains Ownership Of The U.S. NDA And IND Applications For PONVORY From A Johnson & Johnson Company, Which Now Fully Allows Vanda To Commercialize PONVORY In The U.S
Express News | Vanda Pharmaceuticals Announces Completion of Transfer of FDA Marketing Authorization for Ponvory®
Vanda Pharmaceuticals Announces Presentations at SLEEP 2024
WASHINGTON, May 29, 2024 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced participation at SLEEP 2024, to be held in Houston, TX from June 1 through June 5, 2024. The
Express News | Vanda Pharmaceuticals Rejects Revised Unsolicited Acquisition Proposal From Future Pak, Concluding It Undervalues The Company; Board Unanimously Decides Proposal Is Not In The Best Interests Of Shareholders
Comments
$Vanda Pharmaceuticals(VNDA.US$ Vanda Pharmaceuticals Gains Ownership Of The U.S. NDA And IND Applications For PONVORY From A Johnson & Johnson Company, Which Now Fully Allows Vanda To Commercialize PONVORY In The U.S
Benzinga· 1 min ago
Benzinga· 1 min ago
1
$Vanda Pharmaceuticals(VNDA.US$
Vanda Pharmaceuticals Announces Presentations at SLEEP 2024
Vanda Pharmaceuticals has announced its participation in SLEEP 2024, a conference set to take place in Houston, TX from June 1-5, 2024. The company will present four research studies on June 4, 2024, conducted by Dr. Sandra Paulina Smieszek, Head of Genetics. The presentations will cover drug and CRISPR/Cas9 screening of HCN channels, the impact of melanopsin crispants in zebrafish on sleep latency...
Vanda Pharmaceuticals Announces Presentations at SLEEP 2024
Vanda Pharmaceuticals has announced its participation in SLEEP 2024, a conference set to take place in Houston, TX from June 1-5, 2024. The company will present four research studies on June 4, 2024, conducted by Dr. Sandra Paulina Smieszek, Head of Genetics. The presentations will cover drug and CRISPR/Cas9 screening of HCN channels, the impact of melanopsin crispants in zebrafish on sleep latency...
1
$Vanda Pharmaceuticals(VNDA.US$ The stock itself will fly to $10 per share soon. So Future Pak should offer $15 per share, then they might accept it.![]()
Read more